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The Authors Reply: We are responding to Dr David
Naimark’s letter1 regarding our warfarin-related nephropathy
(WRN) paper.2 With respect to Dr Naimark’s comment
regarding the section regimen, we agree that our selection
process was biased to include those with ‘acute illnesses’. We
point out that our selection process likely identiﬁed the sickest
of the patients. However, it would be highly improbable that
this accounts for the cases of ‘presumptive WRN’. That would
have required that all of the cases of unexplained AKI
(presumptive WRN) by chance alone occurred all within 1
week after an increase in international normalized ratio (INR)
to 43.0, but not before or after the increase, as shown in
Figure 1. Note that there was no evidence that AKI occurred
before the increase in INR to 43.0. The fact that the
unexplained AKI instances are strongly and temporally
related to an INR increase 43.0 suggests a mechanistic link
between the INR increase 43.0 and the case of AKI. Further
evidence that the INR increase 43.0 is mechanistically
related to the episodes of AKI is our previous work in
humans1,2 and our animal model in 5/6 nephrectomy rats.3
Taken together, we suggest that we have provided compelling
evidence that our study of ‘presumptive WRN’ is, in fact, a
study of WRN.
Regarding the comment on the mortality hazard associated
with ‘WRN,’ we suggest that Dr Naimark’s interpretation is
implausible and refer to Figure 5. Panels c and d show,
respectively, the hazard ratio for death in the WRN versus no-
WRN patients unadjusted and adjusted for all of the relevant
covariates (those that were signiﬁcantly different between the
WRN and no-WRN patients). As shown, the unadjusted and
the adjusted hazard ratios were comparable and were not
signiﬁcantly different. This indicates that the greater mortality
rate in the WRN patients was not related to their greater
degree of co-morbidity. Indeed, in the covariate model, the
only variable that signiﬁcantly predicted the increased
mortality rate was whether the patient developed presumptive
WRN after the INR increase 43.0.
We agree with the remarks that the alternative hypothesis
could explain why drugs expected to both increase
and decrease glomerular hydrostatic pressure was associated
with WRN and address as such in our paper. The study was
designed to study patients new to warfarin therapy, and the
issue of whether WRN tends to occur early in the course of
the patient’s disease is discussed and based on our detailed
retrospective analysis of 113 patients with chronic kidney
disease. We also point out that WRN can recur in the same
patient.
With regard to Dr Naimark’s contention that the present
results may have been confounded by patients’ illnesses, we
would remark that it is highly improbable.
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The therapeutic tradeoff between
the adverse impacts of a lower
GFR and long-term renal
protection
To the Editor: The recent demonstration of a slower rate of
decline in estimated glomerular ﬁltration rate (eGFR), in
those losartan-treated diabetic patients with the larger acute
fall in eGFR, by Holtkamp et al.1 did not consider the adverse
effects of the lower eGFR in this group, which was still present
at 39 months, despite this group recording twice the number
of adverse renal events (doubling of plasma creatinine level or
end-stage renal disease) when compared to the losartan treated
patients with an acute rise in eGFR.1
Although renal failure may be asymptomatic down to
a glomerular ﬁltration rate (GFR) of circa 20ml/min,
physiological changes of pathological importance occur
much earlier. Examples include increasingly low levels of
1,25-dihydroxyvitamin D as the GFR falls to o80ml/min,2
and changes in physical function in the elderly, as assessed by
the Short Form-36, with an eGFR o45ml/min.3
An additional concern, in assessing the impact of lowering
GFR, is the patient’s actual GFR, given the imprecision of
eGFR, with coefﬁcients of variation against measured GFR
being circa 20–30%.4 That is, with a starting eGFR of
40ml/min some 16% of the patients will have an actual GFR
o30ml/min, with an acute reduction of 30% post treatment
resulting in an actual GFR of circa 20ml/min.
The actual GFR achieved post treatment is important in
assessing the short-term risks. There should be a lower limit
for acceptable acute post-treatment eGFR, based on the
signiﬁcance and risk of possible adverse events, as well as life
expectancy. What that lower limit should be awaits further
study. But 30ml/min would seem a practicable starting point
for a debate on this issue.
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